Online inquiry

IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15718MR)

This product GTTS-WQ15718MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets S gene. The antibody can be applied in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq YP_009724390.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 43740568
UniProt ID P59594
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15718MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1843MR IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AG1-25
GTTS-WQ13737MR IVTScrip™ mRNA-Anti-ERBB2, RC48-0(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RC48-0
GTTS-WQ4870MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, BTCT4465A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BTCT4465A
GTTS-WQ3308MR IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ASN-100
GTTS-WQ4984MR IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA C4G1
GTTS-WQ13578MR IVTScrip™ mRNA-Anti-IL13, QAX-576(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA QAX-576
GTTS-WQ14775MR IVTScrip™ mRNA-Anti-CD40, SGN-40(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SGN-40
GTTS-WQ2977MR IVTScrip™ mRNA-Anti-IL33, ANB020(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ANB020
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW